EP0774121A1 - Amplification de signal chimioluminescent - Google Patents

Amplification de signal chimioluminescent

Info

Publication number
EP0774121A1
EP0774121A1 EP95923075A EP95923075A EP0774121A1 EP 0774121 A1 EP0774121 A1 EP 0774121A1 EP 95923075 A EP95923075 A EP 95923075A EP 95923075 A EP95923075 A EP 95923075A EP 0774121 A1 EP0774121 A1 EP 0774121A1
Authority
EP
European Patent Office
Prior art keywords
surfactant
acridinium
group
enhancer
member selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95923075A
Other languages
German (de)
English (en)
Inventor
Adrian John Murray
Jonathan Grote
Sherri J. St. John
Diethild Thut
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of EP0774121A1 publication Critical patent/EP0774121A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label

Definitions

  • the present invent ion relates to immunoas say ⁇ ut i l i z ing chemi lumine s c ent compounds and , mor e particularly, to the use of surfactants for enhancing the chemiluminescent signal of acridinium sulfonamides .
  • Immunoassays which employ a chemiluminescent label as the signal generating compound are known.
  • chemiluminescence generation and detection in immunoassays is disclosed in W. R. Seitz, "Immunoassay Labels Based on Chemiluminescence and Bioluminescence, " Clinical Biochemistry, 17:120-126 (1984) .
  • the use of acridinium esters as labels for immunoassays and subsequent generation of short-lived chemiluminescence signals from these labels is disclosed in I. Weeks, e_£. a_L. , "Acridinium Esters as Highly Specific Activity Labels in Immunoassays, " Clinical Chemistry. 19:1474-1478 (1984).
  • U.S. Patent No. 4,959,182 describes a method for amplifying the chemiluminescent signal generated from alkaline phosphatase-catalyzed 1,2- dioxetanes by the addition of a surfactant and a fluorescent compound attached to it.
  • U.S. Patent No. 4,927,769 discloses use of certain types of surfactants for enhancing the chemiluminescent signal generated from acridinium ester conjugates.
  • the method uses a first signal generation reagent under acidic conditions and, a second signal generating reagent to increase the pH and trigger the chemiluminescent signal.
  • the acridinium esters require using this two stage process to efficiently emit the signal. This is a problem, however, in that antibody- conjugated acridinium esters are often unstable above certain pH levels due to hydrolysis.
  • chemiluminescent labels have been developed.
  • acridinium sulfonamides are useful chemiluminescent reagents, there presently exists a need to enhance the generated chemiluminescent signal of these compounds in order to improve immunoassay sensitivity and efficiency.
  • a general object of the present invention is to provide enhancement of the chemiluminescent signal of acridinium sulfonamides.
  • Other objects will hereinafter become evident to those skilled in the art.
  • the present invention concerns a method for generating an enhanced chemiluminescent signal from an acridinium sulfonamide compound.
  • the method comprises the step of contacting the acridinium sulfonamide compound with a trigger solution in the presence of an enhancer to obtain a chemiluminescent signal which is about 1.5 to 8 times stronger than would otherwise be generated in the absence of the enhancer.
  • the invention is a method for generating an enhanced chemiluminescent signal from an acridinium sulfonamide compound, the method comprising the step of contacting the acridinium sulfonamide compound with a trigger solution in the presence of an enhancer comprising at least one member selected from the group consisting of (i) nonionic surfactants, (ii) zwitterionic surfactants and (iii) anionic surfactants.
  • the invention further provides a trigger solution for generating a chemiluminescent signal from an acridinium sulfonamide compound.
  • the trigger solution comprises an oxidant and an enhancer.
  • the enhancer comprises a surfactant effective for increasing the intensity of the chemiluminescent signal generated by the acridinium sulfonamide compound.
  • the trigger solution of the invention containing the oxidant and the enhancer, can be provided as a reagent in an immunoassay test kit in which the acridinium sulfonamide compound is included as another reagent.
  • the invention is further directed to an immunoassay test kit having reagents which comprise (a) an acridinium sulfonamide compound; (b) a trigger solution separate from said acridinium sulfonamide; and (3) an enhancer comprising at least one surfactant selected from the group consisting of (i) nonionic surfactants, (ii) zwitterionic surfactants and (iii) anionic surfactants.
  • the acridinium sulfonamide compound can be provided in the form of an acridinium sulfonamide-labeled conjugate for use in a variety of immunoassay formats.
  • the acridinium sulfonamide conjugate can be supplied as one reagent, and a trigger solution containing a mixture of the oxidant and the enhancer can be provided as a second reagent.
  • the trigger solution and the enhancer can be supplied separately from one another.
  • the enhancer can be supplied in the form of a mixture with the acridinium sulfonamide compound.
  • acridinium sulfonamide compound means the chemiluminescent compounds identified by the formula:
  • R, R', R", ⁇ l, and ⁇ 2 are substituents which do not interfere with the chemiluminescent signal provided by such chemiluminescent compounds, with the proviso that R"-X-- and R- ⁇ 2 may be independently hydrogen.
  • R and R" may be spacer arms and X 1 and X 2 may be independently members selected from the group consisting of hydrogen, carboxy, carboalkoxyl, carboxamido, carboaryloxy, cyano, carboximido, isocyanato, isothiocyanato, sulfo, sulfonyl halide, carbonyl halide, N-succinimidyloxycarbonyl and N-succinimidyloxysulfonyl .
  • Y ⁇ is an appropriate counterion, and may be selected from the group consisting of sulfate, alkylsulfate, halosulfate, haloborate, haloacetate, halophosphate, phosphate and halide.
  • the counterion is sulfate or halide.
  • R, R', and R" may independently include a member selected from the group consisting of alkyl, alkylene, aryl, substituted alkyl, substituted alkylene, and substituted aryl groups, such that one or more hydrogens of said member can be replaced by an alkyl, aryl, alkylene, substituted alkyl, substituted alkylene, substituted aryl, alkoxy, aryloxy, halo, amino, protected amino, substituted amino hydroxy, protected hydroxy, oxo, thio, imino, mercapto or substituted mercapto group; or such that one or more carbon atoms of the member can be replaced by a heteroatom.
  • the heteroatom may be selected from the group consisting of nitrogen, phosphorus, sulfur and oxygen.
  • the preferred acridinium sulfonamide compounds for use in the present invention are 10-methyl-N- (2-carboxyethyl) - N-tosyl-9-acridinium carboxamide and 10- (3-sulfopropyl) -N- (2-carboxyethyl) -N-tosyl-9-acridinium carboxamide.
  • the most preferred acridinium sulfonamide is 10- (3- sulfopropyl) -N- (2-carboxyethyl) -N-tosyl-9-acridinium carboxamide.
  • acridinium sulfonamide compounds referenced in Molz ___, al . European Patent Application No. 257,541 (published March 2, 1988) incorporated herein by reference.
  • the acridinium sulfonamide compounds discussed in Molz _ ⁇ __ a_L. have the following general formula:
  • R-*- stands for hydrogen, an alkyl, alkenyl or alkynyl radical with 1 to 10 carbon atoms, a benzyl or aryl group
  • R 2 and R*- 1 stand for hydrogen, an alkyl group with 1 to 4 carbon atoms, a substituted or unsubstituted amino group, a carboxy, alkoxy, cyano, nitro group or halogen
  • R ⁇ represents a radical in which a sulfonamide group is bound directly to the carbonyl group via the nitrogen or a thioalkyl or thioaryl radical of formula II
  • X is a branched or unbranched aliphatic or aromatic group which may also contain heteroatoms
  • R5 is a reactive group which selectively under gentle conditions can enter into a bond with amino, carboxy thiol or other functional groups in substances of biological interest
  • a ⁇ is an anion which does not impair chemiluminescence.
  • acridinium sulfonamide compounds useful in the present invention is disclosed in Mattingly et al . European Patent Application 273,115 published July 6, 1988, incorporated herein by reference. Molz .e_£. al . published European Patent Application No. 257,541 also discusses preparation of acridinium sulfonamides.
  • the acridinium sulfonamide can be oxidized by any oxidant which reacts with the acridinium sulfonamide to yield a product in an electronically excited state. As it returns to the ground state, this product releases energy in the form of light in a chemiluminescent reaction.
  • a "trigger solution” means the solution containing the oxidant which initiates or catalyzes the chemiluminescent reaction.
  • a preferred trigger solution comprises hydrogen peroxide in dilute alkali.
  • the term “enhancer” means a reagent provided by the present invention that increases the total light emission of the chemiluminescent reaction and/or the signal to background noise ratio of the chemiluminescent reaction in comparison to that achieved by the acridinium sulfonamide in the absence of the enhancer.
  • the enhancer is comprised of at least one member selected from the group consisting of nonionic, zwitterionic, and anionic surfactants.
  • Nonionic surfactants are discussed in Surfactant Science and Technology, by Drew Myers, VCH Publishers, Inc., N.Y., 1988, which is incorporated by reference herein.
  • Preferred nonionic surfactants include polyoxyethylenated alkylenated alkylphenols , polyoxyethylenated straight -chain alcohols, polyoxyethylenated sorbitol esters, and alkanolamine-fatty acid condensates.
  • Commercially available nonionic surfactants suitable for use with the present invention include TRITON X-100, TWEEN-20 and BRIJ-35. 1
  • Zwitterionic surfactants are also discussed in Myers, supra .
  • Preferred zwitterionic surfactants are of the formula:
  • R 1 is C 1 -C 16 aliphatic; R 2 and R 4 are methyl or ethyl; and R 3 is C 1 -C 3 aliphatic.
  • Other suitable zwitterionic surfactants include the formula wherein R 1 is C 8 -C 20 aliphatic; R 2 , R 4 , and R 3 are C 1 -C 4 aliphatic.
  • Commercially available zwitterionic surfactants include Tetradecylzwittergent, Hexadecylzwittergent and CHAPS.
  • anionic surfactants are also discussed in Myers, suora .
  • Preferred anionic surfactants include lithium dodecylsulfate, sodium dodecylsulfate and cholic acid.
  • the cationic surfactants Merquat and Cyastat which are of the type disclosed in U.S. Patent No. 4,927,769, provide little or no enhancement of the acridinium sulfonamides.
  • enhancers suitable for use according to the present invention should be soluble in the reagents under the conditions in which the chemiluminescent reaction takes place.
  • the surfactants prescribed for use as enhancers in the present invention enhance the chemiluminescent signal from acridinium sulfonamides such that the intensity of the signal is about 1.5 to 8 times greater, and preferably about 3 to 8 times greater than the signal intensity obtained in the absence of the enhancers.
  • the preferred range for the enhancer present in an immunoassay chemiluminescent reaction is from about 0.25% to about 5% by weight, based on the total weight of the solution in which the chemiluminescent reaction takes place (i.e., the solution containing the enhancer, the trigger solution and the acridinium sulfonamide compound) . More preferably, the enhancer should be present in such solution in an amount of about 2% by weight.
  • the enhancers of the present invention facilitate determination of the presence of an acridinium sulfonamide in a test sample.
  • a particularly useful application of the present invention involves determination of an acridinium sulfonamide conjugate in an immunoassay.
  • an immunoassay test sample suspected of containing an analyte can be contacted with (i) the acridinium sulfonamide compound (i.e., a conjugate of the acridinium sulfonamide with an antigen, hapten, antibody, nucleic acid, etc.); (ii) the trigger solution; and (iii) an enhancer according to the invention, so as to generate an enhanced signal.
  • the trigger and the enhancer can be combined before addition to the acridinium sulfonamide.
  • the acridinium sulfonamide solution and the trigger/enhancer solution can be brought in contact with an analyte either sequentially or simultaneously. Techniques for preparing acridinium sulfonamide conjugates for use in immunoassays are described in Mattingly .e_£. ____. published
  • the present invention can be employed in various heterogeneous and homogeneous immunoassay system formats known in the art.
  • immunoassay system formats include, but are not intended to be limited to, competitive and immunometric techniques.
  • a binding member such as, for example, an immunoglobulin (i.e., a whole antibody or fragment thereof) to bind to a specific analyte from a test sample, wherein a labeled reagent comprising a binding member labeled with a chemiluminescent compound, such as the acridinium sulfonamide described herein, is employed to determine the extent of binding.
  • the extent of binding in such immunoassay system formats is determined by the amount of the chemiluminescent compound present in the labeled reagent which either has or has not participated in a binding reaction with the analyte, wherein the signal which is generated by the chemiluminescent compound as described herein is detected and correlated to the amount of analyte present in the test sample.
  • the test sample can be any material suspected of containing the analyte.
  • the test sample can be used directly as obtained from the source or following a pretreatment to modify the character of the sample.
  • Homogeneous immunoassays typically are performed in a competitive immunoassay format involving a competition between an analyte from a test sample and a labeled reagent for a limited number of receptor binding sites on an antibody to the analyte.
  • the labeled reagent comprises the analyte or analyte-analog labeled with a chemiluminescent compound wherein the concentration of analyte in the test sample determines the amount of the labeled reagent that will specifically bind to the antibody.
  • the amount of the labeled reagent-antibody conjugate produced by such binding may be quantitatively measured and is inversely proportional to the amount of analyte present in the test sample.
  • Heterogeneous immunoassay formats involve a labeled reagent or tracer comprising an analyte, analyte-analog, or an antibody thereto, labeled with a chemiluminescent compound.
  • the assay involves formation of a free species and a bound species.
  • the free species In order to correlate the amount of tracer in one of such species to the amount of analyte present in the test sample, the free species must first be separated from the bound species, which can be accomplished according to methods known in the art employing solid phase materials for the direct immobilization of one of the binding participants in the binding reaction, such as the antibody, analyte-analog, or analyte, wherein one of the binding participants is immobilized on a solid phase material, such as a test tube, beads, particles, microparticles or a matrix of fibrous material, and the like, according to methods known in the art.
  • the solid phase materials can be any solid material to which a binding participant can be immobilized and include, but are not intended to be limited to, beads, magnetic particles, paramagnetic particles, microparticles or macro particles, test tubes, and microtiter plates.
  • Such solid phase materials can be made from synthetic materials, naturally occurring materials, or naturally occurring materials which have been synthetically modified, and include, but are not intended to be limited to, cellulose materials, such as paper, cellulose and cellulose derivatives such as cellulose acetate and nitrocellulose; fiberglass; naturally occurring cloth such as cotton; synthetic cloth such as nylon; porous gels, such as silica, agarose, dextran, and gelatin; porous fibrous matrixes; starch based materials, such as cross-linked dextran chains; ceramic materials; olefin or thermoplastic materials including polyvinyl chloride, polyethylene, polyvinyl acetate, polyamide, polycarbonate, polystyrene, copolymers of vinyl acetate and vinyl chloride, combinations of polyviny
  • Heterogeneous immunoassays can be performed in a competitive immunoassay format wherein, for example, the antibody can be immobilized to a solid phase material whereby upon separation, the signal generated by the chemiluminescent compound of the bound or free species can be detected and correlated to the amount of analyte present in the test sample.
  • Another form of a heterogeneous immunoassay employing a solid phase material is referred to II as a sandwich immunoassay, which involves contacting a test sample containing, for example, an antigen with a protein such as an antibody or another substance capable of binding the antigen, and which is immobilized on a solid phase material.
  • the solid phase material typically is treated with a second antigen or antibody which has been labeled with a chemiluminescent compound.
  • the second antigen or antibody then becomes bound to the corresponding antigen or antibody on the solid phase material and the signal generated by the chemiluminescent compound in the bound or the free species can be detected and correlated to the amount of analyte present in the test sample.
  • test sample means any sample derived from any biological source, such as a physiological fluid, including, blood, saliva, ocular lens fluid, cerebral spinal fluid, sweat, urine, milk, ascites fluid, mucous, synovial fluid, peritoneal fluid, amniotic fluid or the like.
  • the test sample can be pretreated prior to use, such as preparing plasma from blood, diluting viscous fluids, or the like; methods of treatment can involve filtration, distillation, concentration, inactivation of interfering components, and the addition of reagents.
  • other liquid samples can be used such as water, food products and the like for the performance of environmental or food production assays.
  • a solid material suspected of containing the analyte can be used as the test sample.
  • a solid material suspected of containing the analyte can be used as the test sample.
  • the analyte can be any compound or composition to be detected or measured and which has at least one epitope or binding site.
  • analyte means any substance for which there exists a naturally occurring binding member or for which a binding member can be prepared. Analytes include, but are not limited to, toxins, organic compounds, proteins, peptides, microorganisms, amino acids, nucleic acids, hormones, steroids, vitamins, drugs (including those administered for therapeutic purposes as well as those administered for illicit purposes), virus particles and metabolites of or antibodies to any of the above substances.
  • such analytes include, but are not intended to be limited to, ferritin; creatinine kinase MB (CK-MB) ; digoxin; phenytoin,* phenobarbital carbamazepine; vancomycin; gentamicin, theophylline valproic acid; quinidine; luteinizing hormone (LH) follicle stimulating hormone (FSH) ,* estradiol progesterone; IgE antibodies; vitamin B12 micro-globulin glycated hemoglobin (Gly.
  • Hb cortisol; digitoxin; N- acetylprocainamide (NAPA) ; procainamide; antibodies to rubella, such as rubella-IgG and rubella-IgM; antibodies to toxoplasmo ⁇ is, such as toxoplasmosis IgG (Toxo-IgG) and toxoplasmosis IgM (Toxo-lgM) ; testosterone; salicylates; acetaminophen; hepatitis B virus surface antigen (HBsAg) ; antibodies to hepatitis B core antigen, such as anti- hepatitis B core antigen IgG and IgM (Anti-HBC) ; human immune deficiency virus 1 and 2 (HIV-1 and HIV-2); human T- cell leukemia virus 1 and 2 (HTLV-1 and HTLV-2); hepatitis Be antigen (HBeAg) ; antibodies to hepatitis Be antigen (Anti-HBe) ;
  • Drugs of abuse and controlled substances include, but are not intended to be limited to, amphetamine; methamphetamine; barbiturates such as amobarbital, secobarbital, pentobarbital, phenobarbital, and barbital; benzodiazepines such as librium and valium; cannabinoids such as hashish and marijuana; cocaine; fentanyl; LSD; methaqualone; opiates such as heroin, morphine, codeine, hydromorphone, hydrocodone, methadone, oxycodone, oxymorphone and opium; phencyclidine; and propoxyhene.
  • analyte also includes any antigenic substances, haptens, antibodies, macromolecules and combinations thereof. The foregoing is not intended to be a limiting definition.
  • analyte-analog means any substance which cross-reacts with an analyte-specific binding member, although it may do so to a greater or lesser extent than does the analyte itself.
  • the analyte- analog can include a modified analyte as well as a fragmented or synthetic portion of the analyte molecule, so long as the analyte-analog has at least one epitope site in common with the analyte of interest.
  • an analyte-analog is a synthetic peptide sequence which duplicates at least one epitope of the whole-molecule analyte so that the analyte-analog can bind to an analyte- specific binding member.
  • the binding member is a member of the binding pair, i.e., two different molecules wherein one of the molecules specifically binds to the second molecule through chemical or physical means.
  • binding pairs include, as examples without limitation, biotin and avidin, carbohydrates and lectin ⁇ , complementary nucleotide sequences, complementary peptide sequences, effector and receptor molecules, enzyme cofactors and enzymes, enzyme inhibitors and enzymes, a peptide sequence and an antibody specific for the sequence or the entire protein, polymeric acids and bases, dyes and protein binders, peptides and specific protein binders (e.g., ribonuclease, S-peptide and ribonuclease S-protein) , and the like.
  • binding pairs can include members that are analogs of the original binding member, for example, an analyte-analog or a binding member made by a recombinant techniques or molecular engineering.
  • the binding member is an immunoreactant it can be, for example, a monoclonal or polyclonal antibody, a recombinant protein or recombinant antibody, a chimeric antibody, a mixture(s) or fragment (s) of the foregoing, as well as a preparation of such antibodies, peptides and nucleotides for which suitability for use as binding members is well known to those skilled in the art.
  • Immunoassays assays in which the invention can be used include, by way of example, and not by way of limitation, assays for thyroid hormones, cancer markers, W viral antigens or their antibodies, therapeutic drugs, etc.
  • the invention provides a simpler, more sensitive and more convenient chemiluminescent immunoassay than previously described. Simplification results in that the enhancer reagent can be added in a single stage for an effective chemiluminescent immunoassay.
  • a further benefit of the invention is the attainment of markedly improved assay efficiency. Improved efficiency makes it possible to achieve desired assay results using less acridinium sulfonamide conjugate. This benefit results in a substantial reduction in assay cost without sacrificing assay sensitivity.
  • Merquat a cationic surfactant dimethyldiallylammonium chloride
  • TWEEN-20 sorbitan monooleate polyoxyethylene
  • BRIJ-35 laryl alcohol IS ether
  • a Model LB 9501 Luminometer was obtained from Laboratorium Berthold, Wildbad, Germany.
  • the trigger was an alkaline peroxide solution of 0.25 N NaOH containing 0.6% hydrogen peroxide (H 2 0 2 ) which also contained 0.01% antifoam agent.
  • the antifoam agent was Antifoam C Emulsion Sigma No. A-8011 obtained from Sigma Chemical Company, St. Louis, MO. We have not observed any effect of the antifoam agent upon signal intensity output.
  • the acridinium sulfonamide conjugate was diluted with distilled water to give approximately 250,000 counts and was added in the amount of 100 ul to a vial and placed in the luminometer. While the vial was in the measuring position, 300 ul of trigger containing 1% of the selected enhancer was injected into the vial. A control sample was also measured which used a trigger containing no enhancer. The light emitted was measured in the luminometer for two seconds.
  • Table 1 shows the ratios of the signal intensity enhancement exhibited by the chemiluminescent reaction of the acridinium sulfonamide (sulfopropyl) -labeled h-TSH antibody, the acridinium sulfonamide (sulfopropyl) -labeled PSA antibody, and the acridinium sulfonamide (methyl) - labeled PSA antibody over the two second measuring time in l£ the presence and absence of CHAPS, Merquat (cationic), SDS, LDS, TWEEN-20, BRIJ-35, TRITON X-100, CYASTAT (cationic) and cholic acid.
  • Acridinium sulfonamide (sulfopropyl) -labeled h-TSH antibody was prepared, as described in Example 1. Similarly, acridinium sulfonamide (methyl) -labeled h-TSH antibody was prepared.
  • the trigger reagent was as described in Example 1. Method The acridinium sulfonamide conjugates were diluted with distilled water to produce approximately 7,000 counts when triggered without an enhancer. 50 ul of the diluted conjugate and 50 ul of 0.03 N H2SO4 were added to a vial. The acid was necessary to obtain light emission from the ester conjugate. The triggering process was as described in Example 1.
  • Table 2 shows the ratios of the signal intensity enhancement exhibited by the chemiluminescent reaction of ester- labeled folate, the acridinium sulfonamide ( sulfopropyl ) -labeled h-TSH antibody (Ab) , and the acridinium sulfonamide (methyl) -labeled h-TSH antibody (Ab) over the two second measuring time in the presence and absence of TRITON X-100, SDS, Brij-35, TWEEN-20, Hexadecylzwittergent and Tetradecylzwittergent .
  • the enhancers included TRITON X-100 and Tetradecylzwittergent.
  • the wash solution used was a microparticle enzyme immunoassay (MEIA) diluent buffer available from Abbott Diagnostics.
  • MEIA microparticle enzyme immunoassay
  • a suspension containing 50 ul of the magnetic microparticle solid-phase and 50 ul of the PSA standard was incubated at 37 °C for ten minutes.
  • the microparticles were washed two times by subjecting them to a magnetic field.
  • the microparticle pellet was resuspended in 150 ul of the acridinium sulfonamide-labeled PSA antibody solution.
  • This suspension was incubated at 37 °C for 20 minutes after which the microparticles were subjected to a magnetic field and washed four times.
  • the washed microparticles were then mixed with 400 ul of distilled water and placed in the luminometer in contact with trigger solution whereupon the signal was read as described in Example 1.
  • Trigger solutions containing 0.0%, 0.5%, 1.0% and 2.0% TRITON X-100 and Tetradecylzwittergent were used to determine the effect of enhancer concentration on light emission.
  • HBsAg hepatitis B surface antigen
  • h-TSH antibody hepatitis B surface antigen
  • T 3 triiodothyronine antigen
  • the calibrators used were as follows: the calibrator for HBsAg was recalcified human plasma spiked to 0.5 ng/ml with surface antigen, PSA as described in Example 3, and the h-TSH and T 3 calibrators are both from Abbott Diagnostics.
  • h-TSH antibody was labeled with acridinium sulfonamide (sulfopropyl) .
  • PSA antibody, HBsAg antibody and T3 were also separately labeled with the acridinium sulfonamide (sulfopropyl) .
  • the enhancers tested included Tetradecylzwittergent and TRITON X-100.
  • the trigger reagent was an alkaline peroxide solution of 0.25 N NaOH containing 0.45% H 2 O 2 which also contained 0.01% antifoam agent as described in Example 1.
  • the optimal range for the enhancer concentration and the trigger was determined for four different assays.
  • the same standard assay protocol described in Example 3 was used, with the following exceptions.
  • the sample size for the HBsAg and h-TSH assays was 200 ul instead of 50 ul.
  • the second incubation period for the T 3 assay was shortened to ten instead of twenty minutes.
  • the concentrations of ⁇ the enhancers used were 0.5%, 2.3%, and 4.0%.
  • the acridinium sulfonamide conjugate solutions, magnetic microparticles and calibrators were prepared in the same manner described in Example 4.
  • the enhancers tested included Tetradecylzwittergent and TRITON X-100.
  • the trigger was an alkaline peroxide solution of 0.25 N NaOH containing 0.3% H2O2 which also contained 0.01% antifoam agent and 2% of the enhancer.
  • Example 3 The same standard protocol for the assay described in Example 3 was used. The only difference was that the assays were performed with the conjugate concentration at 0.25X, 0.5X and IX the concentration chosen for the unenhanced assay.
  • Table 5 shows the RLU's of the chemiluminescent reaction of sulfopropyl-labeled conjugates of h-TSH, HBsAg and PSA antibodies and T 3 at varying concentrations over the two second measuring time in the presence of TRITON X- 100 and Tetradecylzwittergent. A control contained no enhancer.
  • the enhancer tested was TRITON X-100.
  • the trigger was an alkaline peroxide solution of 0.25 N NaOH containing 0.3%
  • H 2 O 2 which also contained 0.01% antifoam agent and 2% of the enhancer.
  • Results Table 6 shows the ratio of the trigger with the enhancer to the trigger without the enhancer at different pH values.
  • the sulfopropyl acridinium sulfonamide conjugates of h-TSH, HBsAg and PSA antibodies and T 3 were measured over the two second time period in the presence and absence of 2% TRITON X-100.
  • the reagents necessary for practicing the chemiluminescence enhancement method of the present invention in an immunoassay can be provided in the form of a reagent kit where the reagents are in predetermined ratios, so as to optimize sensitivity of the assay in the range of interest.
  • Wet or dry reagents may be used. If dry reagents are used they can be reconstituted prior to use to obtain a desired concentration of the reagents for a particular assay.
  • the reagents may be mixed with various ancillary materials such as members of the signal producing system, buffers, and the like.
  • the trigger is kept separate from the acridinium sulfonamide.
  • the enhancer may be kept separate from or added to either the trigger reagent or the acridinium sulfonamide reagent.
  • the chemiluminescent reaction is then triggered by combining the trigger reagent with the acridinium sulfonamide.
  • a method for generating an enhanced chemiluminescent signal from an acridinium sulfonamide compound comprising the step of contacting the acridinium sulfonamide compound with a trigger solution in the presence of an enhancer to obtain a chemiluminescent signal which is about 1.5 to 8 times stronger than would otherwise be generated in the absence of said enhancer.
  • the surfactant comprises at least one member selected from the group consisting of nonionic surfactants.
  • nonionic surfactant comprises at least one member selected from the group consisting of polyoxyethylenated alkylenated alkylphenols, polyoxyethylenated straight-chain alcohols, polyoxyethylenated sorbitol esters, and alkanolamine-fatty acid condensates.
  • the surfactant comprises at least one member selected from the group consisting of zwitterionic surfactants.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

L'invention concerne un procédé servant à générer un signal chimioluminescent amplifié depuis un composé de sulfonamide d'acridinium et consistant à mettre en contact ledit composé avec une solution d'amorçage en présence d'un amplificateur, de manière à obtenir un signal chimioluminescent, dont la force est supérieure à celle d'un signal qui aurait été généré en l'absence dudit amplificateur. Ce dernier comprend au moins un élément sélectionné dans le groupe constitué par des tensio-actifs non ioniques, des tensio-actifs zwitterioniques et des tensio-actifs anioniques.
EP95923075A 1994-07-15 1995-06-16 Amplification de signal chimioluminescent Withdrawn EP0774121A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27601294A 1994-07-15 1994-07-15
US276012 1994-07-15
PCT/US1995/007642 WO1996002839A1 (fr) 1994-07-15 1995-06-16 Amplification de signal chimioluminescent

Publications (1)

Publication Number Publication Date
EP0774121A1 true EP0774121A1 (fr) 1997-05-21

Family

ID=23054782

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95923075A Withdrawn EP0774121A1 (fr) 1994-07-15 1995-06-16 Amplification de signal chimioluminescent

Country Status (5)

Country Link
EP (1) EP0774121A1 (fr)
JP (1) JPH10502958A (fr)
AU (1) AU2775395A (fr)
CA (1) CA2191613A1 (fr)
WO (1) WO1996002839A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE282827T1 (de) * 1996-09-19 2004-12-15 Daiichi Pure Chemicals Co Ltd Zusammensetzung zur immunohistochemischen anfärbung
AUPQ776800A0 (en) 2000-05-26 2000-06-22 Seba Diagnostics Pty. Ltd. Detection method and reagents
US6895866B2 (en) 2001-08-01 2005-05-24 National Steel Car Limited Rail road freight car with damped suspension
US7004079B2 (en) 2001-08-01 2006-02-28 National Steel Car Limited Rail road car and truck therefor
WO2011060228A1 (fr) * 2009-11-16 2011-05-19 Siemens Healthcare Diagnostics Inc. Composés d'acridinium contenant du zwitterion
JP6494599B2 (ja) 2013-05-14 2019-04-03 シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレーテッドＳｉｅｍｅｎｓ Ｈｅａｌｔｈｃａｒｅ Ｄｉａｇｎｏｓｔｉｃｓ Ｉｎｃ． 分解可能なカチオン界面活性剤および化学発光を増強するためのその利用
CN105158235B (zh) * 2014-06-06 2018-05-08 厦门万泰凯瑞生物技术有限公司 一种吖啶酯增强发光系统
CN110392831B (zh) 2017-01-27 2023-09-05 豪夫迈·罗氏有限公司 用于在相互作用测定中调节信号强度的方法
CN114685418B (zh) * 2020-12-31 2023-06-27 菲鹏生物股份有限公司 用于增强amppd底物的化学发光强度的化合物及其制备方法和增强剂
CN114280289B (zh) * 2021-12-20 2023-10-10 南京诺唯赞医疗科技有限公司 一种磁微粒化学发光检测试剂盒及其检测方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3645292C2 (de) * 1986-08-22 1997-12-11 Hoechst Ag Chemilumineszenzimmunoassays und ein Verfahren zu ihrer Herstellung
US4927769A (en) * 1987-07-08 1990-05-22 Ciba Corning Diagnostics Corp. Method for enhancement of chemiluminescence
KR930702680A (ko) * 1990-11-09 1993-09-09 찰스 엠.브룩 증폭된 불균질 화학발광 면역 검정법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9602839A1 *

Also Published As

Publication number Publication date
AU2775395A (en) 1996-02-16
WO1996002839A1 (fr) 1996-02-01
JPH10502958A (ja) 1998-03-17
CA2191613A1 (fr) 1996-02-01

Similar Documents

Publication Publication Date Title
KR101032172B1 (ko) 자기 입자를 이용한 내부 교정 시스템을 사용하는 유동분석 장치
KR100994345B1 (ko) 유체공학 기반 분석 장치
US7867781B2 (en) Detection methods
US6251581B1 (en) Assay method utilizing induced luminescence
EP1047943B1 (fr) Dispositif chromatographique et procede de detection d'un analyte dans un echantillon de sang
US5710006A (en) Reagents for specific binding assays
KR100994316B1 (ko) 자기 결합 분석용 자가-교정 시스템
JPH0666803A (ja) 固相へ抗体をコーティングするための２段階法
JPH04233461A (ja) 同時アッセイ法
EP0774121A1 (fr) Amplification de signal chimioluminescent
JP3284016B2 (ja) 非特異的反応抑制剤
US6121006A (en) Immunoassay utilizing two incubations with labeled antigen
JP4253071B2 (ja) リウマチ因子による干渉の低下
EP0566629A4 (fr) Determination simultanee d'analytes multiples a l'aide d'une technique de chimioluminescence heterogene a resolution temporelle.
CA2008100A1 (fr) Methode de dosage de substances detectables par des methodes immunologique
KR20140145121A (ko) 면역분석 방법 및 시약
JPH11248706A (ja) 非特異的吸着防止剤
WO1991006559A1 (fr) Emploi d'immunoglobuline polymerisee afin de reduire la frequence de reactions positives fausses dans des immunoanalyses
JPH08294397A (ja) 免疫学的活性物質の測定方法
JP5021120B2 (ja) 環状ヌクレオチドモノホスフェートのための競合的化学ルミネセンス検定
JP2000028614A (ja) 免疫学的検査方法および免疫学的検査キット
JPH0192661A (ja) 免疫分析方法
EP0599803B1 (fr) Procédé de décèlement d'anticorps et d'antigènes
JPH11352127A (ja) 非特異的吸着防止剤
CN108414736B (zh) 一种利用化学发光增强子修饰的抗体检测目标物的方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970113

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE ES FR GB IT LI NL

RIN1 Information on inventor provided before grant (corrected)

Inventor name: THUT, DIETHILD

Inventor name: ST. JOHN, SHERRI, J.

Inventor name: GROTE, JONATHAN

Inventor name: MURRAY, ADRIAN, JOHN

17Q First examination report despatched

Effective date: 19980514

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19981127